1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow JB100: new trials by email Literature Review of JB100 trials Research Report on JB100
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) Avelumab, Sacituzumab Govitecan (SG), M6223 - Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2 | Active not recruiting | EMD Serono Research & Development Institute, Inc. | 256 | 2022-08-17 | 2026-09-28 |
Carcinoma, Transitional Cell (1) · Urinary Bladder Neoplasms (1)
EMD Serono Research & Development Institute, Inc. (1)
Australia (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1) · United States (1)
2023 (1)